For biopharma leaders, BD&L is more than a pathway to pipeline growth—it’s a series of billion-dollar decisions in a high-risk, fast-changing market. Yet history shows even promising science doesn’t guarantee commercial success.
Recent analyses reveal:
- <30% of drug launches miss sales forecasts, often due to market access and pricing challenges
- ~30% of deals have been overvalued, while ~20% struggled from competitive pressures or misalignment
- Tens of billions in anticipated deal value have been erased, particularly in competitive areas like oncology and neurology
In this 30-minute session, our experts will explore the hidden risks that derail BD&L success and how a full-spectrum perspective across science, clinical, regulatory, and commercial strategy can change the outcome.
Key questions we’ll address:
- How can biopharma leaders avoid overpaying for assets in crowded therapeutic areas?
- What are the most common blind spots in traditional BD&L due diligence?
- How early in development can critical risks—and opportunities—be identified?
- What differentiates a truly integrated BD&L strategy from a standard diligence exercise?
The stakes have never been higher. Ensure your next deal delivers sustainable value.
Speakers:
- Tim Barder, PhD, SVP, Strategy Consulting, Lumanity
- John Westwood, PhD, SVP, Strategy Consulting, Lumanity
